Company Filing History:
1 out of 96 
1 out of 321 
Years Active: 2010
Title: Mi-Young Park: Innovator in Monoclonal Antibody Research
Introduction
Mi-Young Park, a prominent inventor located in Daejeon, South Korea, has significantly contributed to the field of biomedical research with a focus on monoclonal antibodies. With two patents to her name, she is dedicated to advancing the understanding and treatment of complex diseases, particularly cancer.
Latest Patents
Among Mi-Young Park's notable inventions is a patent related to a monoclonal antibody specific for the N-myc downstream regulated gene 2 (NDRG2) protein. This patent outlines a comprehensive method for producing a cell line that generates the monoclonal antibody, as well as techniques for measuring the quantity and quality of the NDRG2 protein. Given that NDRG2 is a cancer-related factor expressed in dendritic cells, this innovation has the potential to enhance research and therapeutic strategies for intractable diseases.
Another significant patent covers IL-32 monoclonal antibodies and their applications. This invention furnishes diagnostic methods and kits—such as ELISA and Western blot—that utilize monoclonal antibodies specific for interleukin-32 (IL-32). Such advancements could prove valuable in both clinical diagnostics and therapeutic interventions.
Career Highlights
Mi-Young Park has had an impactful career, marked by her collaborations with esteemed institutions. She has worked with the Konkuk University Industrial Cooperation Corporation and the Korea Research Institute of Bioscience and Biotechnology, where her research has pioneered new avenues in antibody technology.
Collaborations
Throughout her career, Mi-Young has collaborated with professionals such as Ki-Hong Kim and Jung-Hyun Shim. These partnerships have fostered innovative solutions and furthered the reach of her research.
Conclusion
Mi-Young Park's work exemplifies the critical intersection of innovation and biotechnology. Her patents not only contribute to scientific knowledge but also offer promising tools for clinical applications, especially in the context of cancer treatment. As she continues her research journey, Mi-Young Park will undoubtedly influence the future of medical science and therapeutic development.